{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:47Z","timestamp":1777289087504,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beh\u00e7et\u2019s Disease Research Committee, Health and Labour Sciences Research Grant","award":["23FC1020"],"award-info":[{"award-number":["23FC1020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10384-025-01206-2","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:35:05Z","timestamp":1745969705000},"page":"798-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and safety of biosimilar infliximab CT-P13 in the treatment of refractory uveitis associated with Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"69","author":[{"given":"Chiuping","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsukata","family":"Kawagoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hirahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Mizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"1206_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G. Beh\u00e7et\u2019s disease. N Engl J Med. 1999;341:1284\u201391.","journal-title":"N Engl J Med"},{"key":"1206_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004397-200604620-00017","volume":"46","author":"PA Yates","year":"2006","unstructured":"Yates PA, Michelson JB. Beh\u00e7et disease. Int Ophthalmol Clin. 2006;46:209\u201333.","journal-title":"Int Ophthalmol Clin"},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.revmed.2013.10.011","volume":"35","author":"H Zeghidi","year":"2014","unstructured":"Zeghidi H, Saadoun D, Bodaghi B. Ocular manifestations in Beh\u00e7et\u2019s disease. Rev Med Interne. 2014;35:97\u2013102.","journal-title":"Rev Med Interne"},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77:808\u201318.","journal-title":"Ann Rheum Dis"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Br\u00e9zin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018;125:757\u201373.","journal-title":"Ophthalmology"},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"1095423","DOI":"10.3389\/fmed.2023.1095423","volume":"10","author":"M Takeuchi","year":"2023","unstructured":"Takeuchi M, Usui Y, Namba K, Keino H, Takeuchi M, Takase H, et al. Ten-year follow-up of infliximab treatment for uveitis in patients with Beh\u00e7et\u2019s disease: a multicenter retrospective study. Front Med (Lausanne). 2023;10:1095423.","journal-title":"Front Med (Lausanne)"},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomized, double-blind, non-inferiority trial. Lancet. 2017;389:2304\u201316.","journal-title":"Lancet"},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2017.02.003","volume":"79","author":"Y Komaki","year":"2017","unstructured":"Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases: a systematic review and meta-analysis. J Autoimmun. 2017;79:4\u201316.","journal-title":"J Autoimmun"},{"key":"1206_CR9","first-page":"55","volume":"37","author":"E Nikiphorou","year":"2019","unstructured":"Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, Paalanen K, et al. Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care. Clin Exp Rheumatol. 2019;37:55\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","volume":"18","author":"DH Yoo","year":"2016","unstructured":"Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:82.","journal-title":"Arthritis Res Ther"},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2217\/imt.14.109","volume":"7","author":"J Braun","year":"2015","unstructured":"Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy. 2015;7:73\u201387.","journal-title":"Immunotherapy"},{"key":"1206_CR12","first-page":"171","volume":"36","author":"CR Holroyd","year":"2018","unstructured":"Holroyd CR, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, et al. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis. Clin Exp Rheumatol. 2018;36:171\u20132.","journal-title":"Clin Exp Rheumatol"},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","volume":"76","author":"JL Nam","year":"2017","unstructured":"Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1113\u201336.","journal-title":"Ann Rheum Dis"},{"key":"1206_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/mr\/roab068","volume":"32","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, et al. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients na\u00efve to or switched from biologics. Mod Rheumatol. 2022;32:718\u201327.","journal-title":"Mod Rheumatol"},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data results of the first international workshop. Am J Ophthalmol. 2005;140:509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.55563\/clinexprheumatol\/r4gnxm","volume":"39","author":"B S\u00f6zeri","year":"2021","unstructured":"S\u00f6zeri B, Karde\u015f E, Sal\u0131 E, \u00c7ak\u0131r D, Demir F. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis. Clin Exp Rheumatol. 2021;39:907\u201312.","journal-title":"Clin Exp Rheumatol"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/09273948.2023.2244071","volume":"32","author":"F Zaguia","year":"2024","unstructured":"Zaguia F, Randerson EL, Moorthy RS, Goldstein DA. Efficacy of biosimilar infliximab-dyyb in non-infectious uveitis. Ocul Immunol Inflamm. 2024;32:1517\u201321.","journal-title":"Ocul Immunol Inflamm"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3389\/fphar.2019.01468","volume":"10","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Emmi G, Sgheri A, Lopalco G, Sota J, et al. The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol. 2019;10:1468.","journal-title":"Front Pharmacol"},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ajo.2020.10.013","volume":"225","author":"N Kumar","year":"2021","unstructured":"Kumar N, Follestad T, Sen HN, Austeng D. A systematic switch from originator infliximab to biosimilar infliximab in patients with non-infectious uveitis. Am J Ophthalmol. 2021;225:178\u201384.","journal-title":"Am J Ophthalmol"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11739-018-1970-3","volume":"14","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Cantarini L, Emmi G, Prisco D, Iannone F. Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Beh\u00e7et\u2019s disease. Intern Emerg Med. 2019;14:719\u201322.","journal-title":"Intern Emerg Med"},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","volume":"4","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassar\u00e0 E, Kaloudi O. Rapid loss of efficacy of biosimilar infliximab in three patients with Beh\u00e7et\u2019s disease after switching from infliximab originator. Eur J Rheumatol. 2017;4:288\u201390.","journal-title":"Eur J Rheumatol"},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s40264-023-01340-1","volume":"46","author":"T Takeuchi","year":"2023","unstructured":"Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, et al. Real-world safety and efficacy of biosimilar CT-P13 in patients with immune-mediated inflammatory diseases: integrated analysis of three Japanese prospective observational studies. Drug Saf. 2023;46:991\u20131005.","journal-title":"Drug Saf"},{"key":"1206_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40259-020-00421-2","volume":"34","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34:513\u201328.","journal-title":"BioDrugs"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajo.2020.08.005","volume":"225","author":"JD Deaner","year":"2021","unstructured":"Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, et al. Recurrence rates of inflammation after switching from the originator infliximab to biosimilar infliximab-abda for noninfectious uveitis. Am J Ophthalmol. 2021;225:172\u20137.","journal-title":"Am J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01206-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01206-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:49:40Z","timestamp":1757162980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01206-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01206-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C. Lee, None; M. Takeuchi, None; T. Kawagoe, None; J. Nakamura, None; E. Shibuya, None; M. Ishihara, None; N. Yamada, None; Y. Mizuki, None; A. Meguro, None; Y. Kirino, None; Y. Soejima, None; L. Hirahara, None; Y. Iizuka, None; N. Mizuki, None.Additional Information Coauthor Masaki Takeuchi, MD, died September 21, 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}